Analysts See $-0.28 EPS for vTv Therapeutics Inc. (VTVT)

April 17, 2018 - By Adrian Mccoy

Analysts expect vTv Therapeutics Inc. (NASDAQ:VTVT) to report $-0.28 EPS on May, 2.They anticipate $0.16 EPS change or 36.36 % from last quarter’s $-0.44 EPS. After having $-0.44 EPS previously, vTv Therapeutics Inc.’s analysts see -36.36 % EPS growth. The stock increased 43.25% or $0.36 during the last trading session, reaching $1.19. About 9.11M shares traded or 2037.37% up from the average. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 34.95% since April 18, 2017 and is downtrending. It has underperformed by 46.50% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $39.05 million. The company's drug candidate for the treatment of Alzheimer's disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

vTv Therapeutics Inc. (NASDAQ:VTVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.